evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 4 · 80%

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

BCVA: loss of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Six or more lines visual acuity lost · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to lower loss of 6 or more lines (30 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Gain of 3 or more lines of visual acuity · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to higher gain of 3 or more lines (15 or more letters) compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Adverse effects: acute severe visual acuity decrease · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin showed no clear difference in adverse effects: acute severe visual acuity decrease compared with photodynamic therapy with 5% dextrose (moderate certainty).

1 finding from 1 review

Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose

Adverse effects: infusion‐related back pain · people with neovascular age‐related macular degeneration

Photodynamic therapy with verteporfin leads to higher adverse effects: infusion‐related back pain compared with photodynamic therapy with 5% dextrose (high certainty).

1 finding from 1 review